Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 8Recruiting 4Terminated 3Withdrawn 2Not yet recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 439Carboplatin 322Nivolumab 298Cyclophosphamide 286Specimen Handling 271Magnetic Resonance Spectroscopy 259Cisplatin 250Paclitaxel 249Radiotherapy 230Dexamethasone 184Biopsy 182Gemcitabine 180durvalumab 171atezolizumab 152Doxorubicin 141Rituximab 138Lenalidomide 136Ipilimumab 134Docetaxel 132Bevacizumab 132Radiation 121Capecitabine 120Oxaliplatin 116Etoposide 116Radiosurgery 113Fluorouracil 112Pemetrexed 109fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Vancomycin × Clear all
NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06540391 2025-09-26

MELODY-1

Microbiotica Ltd

Phase 1 Active not recruiting
41 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡